Home > Boards > US OTC > Biotechs >

Zealand Pharma A/S (ZLDPF)

Add ZLDPF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 11/21/2016 9:29:27 PM - Followers: 0 - Board type: Free - Posts Today: 0

Zealand Pharma A/S Smedeland 36 Glostrup Copenhagen, 2600 Denmark Phone: 45 88 77 36 00 Fax: 45 88 77 38 98 Website: Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide medicines in Denmark. It offers Lyxumia (Lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company is also developing Lantus (LixiLan), which is in Phase III clinical trials for the treatment of type 2 diabetes; Danegaptide that is in Phase II clinical trials to treat cardiac reperfusion injuries; and Elsiglutide, a GLP-2 receptor agonist, which is in Phase IIb clinical trials for the treatment of chemotherapy-induced diarrhea in patients with colorectal cancer. In addition, it is developing ZP4207 that is in Phase I clinical trials to treat hypoglycemia in diabetes; and ZP2929, a dual acting glucagon/GLP-1 peptide receptor agonist, which is in Phase I clinical trials for the treatment of diabetes and/or obesity. The company has license agreements and partnerships with Sanofi S.A., Helsinn Healthcare S.A., Boehringer Ingelheim International GmbH, and Eli Lilly. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#3   PR Release - FDA approval - Type II Diabetes. Trading2retire 11/21/16 09:29:27 PM
#2   $ZLDPF recent news/filings stocktrademan 09/16/15 11:49:35 AM
#1   $ZLDPF recent news/filings stocktrademan 06/11/15 03:14:17 PM